BC Platforms is a partner in BRECISE (Biomarker Research and Evaluation for Clinical Implementation and Supporting Systems Enhancement), a five-year multidisciplinary research initiative co-funded by the Innovative Health Initiative (IHI) under the Horizon Europe programme. The project officially launched in Madrid on March 20, 2025, and runs from January 1, 2025, through 2029.
What Is BRECISE?
BRECISE brings together over 30 public and private partners from across Europe. Its goal is to improve how we diagnose, treat, and monitor prostate and bladder cancers. The project focuses on biomarkers—biological indicators that help guide treatment decisions.
Despite major advances in cancer research, reliable biomarkers are still rare in everyday care. BRECISE aims to fix this gap by combining clinical data with Next-Generation Sequencing (NGS), artificial intelligence (AI), and ex vivo drug testing. This integrated approach will help match patients with the treatments that are most likely to work for them.
BC Platforms’ Role
BC Platforms contributes its expertise in data management and integration. Our team is helping build the foundation for a structured, regulation-ready system that moves biomarkers from discovery into clinical use.
This work will support better risk stratification and more personalized care. It will also help healthcare systems use their resources more effectively and improve patient outcomes across Europe.
What the Project Focuses On
BRECISE targets four critical areas in prostate and bladder cancer:
-
Prostate cancer active surveillance: Helping avoid overtreatment by identifying which patients truly need care.
-
High-risk prostate cancer: Supporting better pre-surgery decisions through improved therapy planning.
-
Bladder cancer therapy resistance: Spotting patients who won’t respond to BCG treatment early (Bacillus Calmette-Guérin, a standard form of immunotherapy).
-
Metastatic bladder cancer: Predicting responses to immunotherapy to avoid delays and reduce side effects.
Why This Matters
For patients, BRECISE offers earlier and more accurate diagnoses. It also helps avoid unnecessary treatments and speeds up changes when therapies stop working.
For healthcare systems, the project supports more efficient treatment allocation. It reduces waste and helps make precision medicine part of routine care—aligned with key EU frameworks like the European Health Data Space and the AI Act.
A Strong European Partnership
BRECISE is a truly collaborative effort. It unites experts from academia, research, industry, healthcare, and patient groups. Together, we are working to turn scientific discoveries into real-world impact—and to set new standards for personalized cancer treatment.
- Read the Press Release: https://euapm.eu/app/uploads/2025/03/Revolutionizing-Cancer-Care_BRECISE-Project-Launches-in-Madrid-to-Pioneer-Precision-Oncology-1.pdf
- Website under construction: https://brecise.eu
This project has received funding from the Innovative Health Initiative Joint Undertaking (IHI JU) under Grant Agreement No. 101194784. The JU receives support from the European Union’s Horizon Europe research and innovation programme, COCIR, EFPIA, EuropaBio, MedTech Europe, and Vaccines Europe.
